Literature DB >> 25753742

Ikaros and leukaemia.

Linda Olsson1, Bertil Johansson.   

Abstract

The IKZF1 gene at 7p12.2 codes for IKAROS (also termed IKZF1), an essential transcription factor in haematopoiesis involved primarily in lymphoid differentiation. Its importance is underlined by the fact that deregulation of IKAROS results in leukaemia in both mice and men. During recent years, constitutional as well as acquired genetic changes of IKZF1 have been associated with human disease. For example, certain germline single nucleotide polymorphisms in IKZF1 have been shown to increase the risk of some disorders and abnormal expression and somatic rearrangements, mutations and deletions of IKZF1IKZF1) have been detected in a wide variety of human malignancies. Of immediate clinical importance is the fact that ΔIKZF1 occurs in 15% of paediatric B-cell precursor acute lymphoblastic leukaemia (BCP ALL) and that the presence of ΔIKZF1 is associated with an increased risk of relapse and a poor outcome; in some studies such deletions have been shown to be an independent risk factor also when minimal residual disease data are taken into account. However, cooperative genetic changes, such as ERG deletions and CRLF2 rearrangements, may modify the prognostic impact of ΔIKZF1, for better or worse. This review summarizes our current knowledge of IKZF1 abnormalities in human disease, with an emphasis on BCP ALL.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  IKZF1; deletion; leukaemia; mutation; prognosis

Mesh:

Substances:

Year:  2015        PMID: 25753742     DOI: 10.1111/bjh.13342

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  26 in total

1.  IKZF1 gene polymorphisms increased the risk of childhood acute lymphoblastic leukemia in an Iranian population.

Authors:  Gholamreza Bahari; Mohammad Hashemi; Majid Naderi; Mohsen Taheri
Journal:  Tumour Biol       Date:  2016-01-21

2.  Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency.

Authors:  David Boutboul; Hye Sun Kuehn; Zoé Van de Wyngaert; Julie E Niemela; Isabelle Callebaut; Jennifer Stoddard; Christelle Lenoir; Vincent Barlogis; Catherine Farnarier; Frédéric Vely; Nao Yoshida; Seiji Kojima; Hirokazu Kanegane; Akihiro Hoshino; Fabian Hauck; Ludovic Lhermitte; Vahid Asnafi; Philip Roehrs; Shaoying Chen; James W Verbsky; Katherine R Calvo; Ammar Husami; Kejian Zhang; Joseph Roberts; David Amrol; John Sleaseman; Amy P Hsu; Steven M Holland; Rebecca Marsh; Alain Fischer; Thomas A Fleisher; Capucine Picard; Sylvain Latour; Sergio D Rosenzweig
Journal:  J Clin Invest       Date:  2018-06-11       Impact factor: 14.808

Review 3.  Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.

Authors:  Sarah A Holstein; Philip L McCarthy
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 4.  Childhood acute lymphoblastic leukemia: Integrating genomics into therapy.

Authors:  Sarah K Tasian; Mignon L Loh; Stephen P Hunger
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

5.  IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.

Authors:  Chunhua Song; Zheng Ge; Yali Ding; Bi-Hua Tan; Dhimant Desai; Krishne Gowda; Shantu Amin; Raghavendra Gowda; Gavin P Robertson; Feng Yue; Suming Huang; Vladimir Spiegelman; Jonathon L Payne; Mark E Reeves; Zafer Gurel; Soumya Iyer; Pavan Kumar Dhanyamraju; Meixian Xiang; Yuka Imamura Kawasawa; Nathalia M Cury; José Andrés Yunes; Mary McGrath; Joe Schramm; Ruijun Su; Yiping Yang; Zhijun Zhao; Xiaoguang Lyu; Markus Muschen; Kimberly J Payne; Chandrika Gowda; Sinisa Dovat
Journal:  Blood       Date:  2020-09-24       Impact factor: 22.113

Review 6.  The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.

Authors:  P Lee; R Bhansali; S Izraeli; N Hijiya; J D Crispino
Journal:  Leukemia       Date:  2016-06-10       Impact factor: 11.528

7.  A unique mutator phenotype reveals complementary oncogenic lesions leading to acute leukemia.

Authors:  Mianmian Yin; Timour Baslan; Robert L Walker; Yuelin J Zhu; Amy Freeland; Toshihiro Matsukawa; Sriram Sridharan; André Nussenzweig; Steven C Pruitt; Scott W Lowe; Paul S Meltzer; Peter D Aplan
Journal:  JCI Insight       Date:  2019-12-05

8.  Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT.

Authors:  Sebastian Giebel; Myriam Labopin; Gerard Socié; David Beauvais; Stefan Klein; Eva Maria Wagner-Drouet; Didier Blaise; Stephanie Nguyen-Quoc; Jean Henri Bourhis; Anne Thiebaut; Hélène Labussière-Wallet; Amandine Charbonnier; Ana Berceanu; José Luis Diez-Martin; Nathalie Fegueux; Jordi Esteve; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2020-11-25       Impact factor: 5.483

9.  Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.

Authors:  Zheng Ge; Chunhua Song; Yali Ding; Bi-Hua Tan; Dhimant Desai; Arati Sharma; Raghavendra Gowda; Feng Yue; Suming Huang; Vladimir Spiegelman; Jonathon L Payne; Mark E Reeves; Soumya Iyer; Pavan Kumar Dhanyamraju; Yuka Imamura; Daniel Bogush; Yevgeniya Bamme; Yiping Yang; Mario Soliman; Shriya Kane; Elanora Dovat; Joseph Schramm; Tommy Hu; Mary McGrath; Zissis C Chroneos; Kimberly J Payne; Chandrika Gowda; Sinisa Dovat
Journal:  Leukemia       Date:  2021-02-02       Impact factor: 11.528

Review 10.  IKAROS-Associated Diseases in 2020: Genotypes, Phenotypes, and Outcomes in Primary Immune Deficiency/Inborn Errors of Immunity.

Authors:  Hye Sun Kuehn; Cristiane J Nunes-Santos; Sergio D Rosenzweig
Journal:  J Clin Immunol       Date:  2021-01-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.